"Idasanutlin Promising for High-Risk Polycythemia Vera and Essential Thrombocytopenia" - Janelle Brady
Results from a phase 1 trial performed by researchers at the Icahn School of Medicine at Mount Sinai indicate that idasanutlin is a promising novel agent for the treatment of polycythemia vera and essential thrombocytopenia. “Previously, MDM2 protein levels were shown to be up-regulated in PV/ET CD34+ cells and exposure to a nutlin, an MDM2 antagonist, induced activation of the TP53 pathway and selective depletion of PV hematopoietic stem and progenitor cells,” said John Mascarenhas, MD, associate professor of hematology and medical oncology at the Icahn School of Medicine at Mount Sinai. Dr. Mascarenhas and his team also concluded, “These data indicate that idasanutlin is a promising novel agent for PV and is currently being evaluated in a global phase 2 trial.”
— John O. Mascarenhas, MD, Associate Professor, Medicine, Hematology and Medical-Oncology, Director, The Adult Leukemia Program, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
